Theravance Uses Organ-Selective R&D To Advance GI, Pulmonary Candidates

 
• By Joseph Haas

Company develops selective JAK inhibitors for IBD and pulmonary disease that are intended to clear the body before systemic side effects can occur. It also has a drug candidate for NOH that analysts think is underappreciated.

Back view image of young businessman standing against business sketch
Theravance expects 2021 to be a year of advancement for its pipeline

More from Business

More from Scrip